Trial Profile
Multicenter randomized crossover study about Every Second Day administration of Vonoprazan for the maintenance treatment of erosive GERD
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 05 Apr 2022
Price :
$35
*
At a glance
- Drugs Vonoprazan (Primary) ; Lansoprazole
- Indications Gastro-oesophageal reflux
- Focus Therapeutic Use
- 01 Mar 2022 Results usefulness and superiority of vonoprazan assessing usefulness and superiority of vonoprazan administered every second day over PPIs in the maintenance therapy of erosive GERD, published in the Journal of Gastroenterology
- 30 Dec 2018 Status changed from not yet recruiting to active, no longer recruiting.
- 22 Dec 2017 New trial record